Consumer medicine information

Seebri Breezhaler

Glycopyrronium

BRAND INFORMATION

Brand name

Seebri Breezhaler

Active ingredient

Glycopyrronium

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Seebri Breezhaler.

SUMMARY CMI

SEEBRI® BREEZHALER®

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using SEEBRI BREEZHALER?

SEEBRI BREEZHALER contains the active ingredient glycopyrronium bromide (glycopyrrolate). SEEBRI BREEZHALER is used to treat chronic obstructive pulmonary disease (COPD). This is a serious lung condition caused by damage to the lungs.

For more information, see Section 1. Why am I using SEEBRI BREEZHALER? in the full CMI.

2. What should I know before I use SEEBRI BREEZHALER?

Do not use if you have ever had an allergic reaction to SEEBRI BREEZHALER or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use SEEBRI BREEZHALER? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with SEEBRI BREEZHALER and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use SEEBRI BREEZHALER?

  • Your doctor will advise you of the appropriate dose.
  • Inhale the contents of one capsule once daily.

More instructions can be found in Section 4. How do I use SEEBRI BREEZHALER? in the full CMI.

5. What should I know while using SEEBRI BREEZHALER?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using SEEBRI BREEZHALER.
  • Use this medicine exactly as prescribed by your doctor or pharmacist.
  • Tell your doctor immediately if you experience difficulties in breathing.
Things you should not do
  • Do not stop using this medicine suddenly.
  • Do not use this medicine to treat any other problems unless your doctor tells you to.
  • Do not swallow SEEBRI BREEZHALER capsules.
Driving or using machines
  • Be careful before you drive or use any machines or tools until you know how SEEBRI BREEZHALER affects you.
Drinking alcohol
  • Tell your doctor if you drink alcohol.
Looking after your medicine
  • Do not store above 30°C.
  • The capsules must always be stored in the blister pack to protect from moisture and light.

For more information, see Section 5. What should I know while using SEEBRI BREEZHALER? in the full CMI.

6. Are there any side effects?

Less serious side effects include dry mouth, vomiting, diarrhoea, difficulty sleeping, fatigue, unusual weakness, headache, numbness, stomach discomfort, sinus congestion, chesty cough, sore throat, hoarse voice, pain in muscles, bones, joints, neck, arms or legs, rash, itching. Serious side effects include difficulty in breathing or swallowing, signs of an allergic reaction (swelling of tongue, lips and face, skin rash, itching and hives), difficulty breathing with wheezing or coughing, fast or irregular heartbeats, chest pain, swelling mainly of the tongue, lips, face and throat, excessive thirst or hunger and frequent urination, difficulty passing urine or painful urination.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

SEEBRI® BREEZHALER®

Active ingredient: Glycopyrronium bromide (glycopyrrolate)

Consumer Medicine Information (CMI)

This leaflet provides important information about using SEEBRI BREEZHALER. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using SEEBRI BREEZHALER.

Where to find information in this leaflet:

1. Why am I using SEEBRI BREEZHALER?
2. What should I know before I use SEEBRI BREEZHALER?
3. What if I am taking other medicines?
4. How do I use SEEBRI BREEZHALER?
5. What should I know while using SEEBRI BREEZHALER?
6. Are there any side effects?
7. Product details

1. Why am I using SEEBRI BREEZHALER?

SEEBRI BREEZHALER contains the active ingredient glycopyrronium bromide (glycopyrrolate). SEEBRI BREEZHALER belongs to a group of medicines called bronchodilators. They help to relax the muscles around your airways in the lungs and keep them open, making breathing easier.

SEEBRI BREEZHALER is used to treat chronic obstructive pulmonary disease (COPD). It is a serious lung condition caused due to damage to the lungs. The damage results in irritation and swelling inside the airways. This limits the airflow into and out of the lungs. COPD symptoms include shortness of breath, cough that brings up mucus, chest discomfort.

2. What should I know before I use SEEBRI BREEZHALER?

Warnings

Do not use SEEBRI BREEZHALER if:

  • you are allergic to glycopyrronium bromide (glycopyrrolate), or any of the ingredients listed at the end of this leaflet. Always check the ingredients to make sure you can use this medicine.

Symptoms of allergic reactions include swelling of the tongue, lips, and face, difficulties in breathing or swallowing, hives or skin rash.

Check with your doctor if you:

  • have any kidney problems
  • suffer from an eye problem called narrow-angle glaucoma
  • have difficulty passing urine
  • have heart problems.

Do not use SEEBRI BREEZHALER in children under 18 years of age.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

SEEBRI BREEZHALER is not recommended for use during pregnancy.

Your doctor will advise you regarding the possible risks and benefits of using SEEBRI BREEZHALER during pregnancy.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

It is unknown whether the active ingredients in SEEBRI BREEZHALER pass into breast milk.

Your doctor will advise you regarding the possible risks and benefits of using SEEBRI BREEZHALER during breast feeding.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with SEEBRI BREEZHALER and affect how it works.

Do not take SEEBRI BREEZHALER with anticholinergic drugs such as ipratropium, oxitropium or tiotropium.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect SEEBRI BREEZHALER.

4. How do I use SEEBRI BREEZHALER?

How much to use

  • Your doctor will advise you of the appropriate dose.
  • The dose for adults is inhaling the contents of one capsule once daily.
  • Follow the instructions provided and use SEEBRI BREEZHALER until your doctor tells you to stop.
  • Do not to take more than one capsule in a day.

When to use SEEBRI BREEZHALER

SEEBRI BREEZHALER should be used at about the same time each day.

How to use SEEBRI BREEZHALER

  • Carefully read the instructions and follow the diagrams inside the carton that show you how to use the BREEZHALER properly.
  • Use SEEBRI capsules only for oral inhalation using the BREEZHALER inhaler.
  • Do not swallow the SEEBRI BREEZHALER capsules.
  • Keep the capsules in the blister pack and only remove them before using.
  • Peel the backing away from the blister pack to open it; do not push the capsule through the foil.
  • If you do not understand how to use the inhaler, ask your doctor or pharmacist for advice.

If you forget to use SEEBRI BREEZHALER

SEEBRI BREEZHALER should be used regularly at the same time each day. If you miss your dose at the usual time, take it as soon as possible and then go back to using it as you would normally do.

Do not take more than one dose in a day.

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Do not take a double dose to make up for the dose you missed.

If you use too much SEEBRI BREEZHALER

If you think that you have used too much SEEBRI BREEZHALER, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using SEEBRI BREEZHALER?

Things you should do

Call your doctor straight away if you:

  • develop any allergic reaction to SEEBRI BREEZHALER
  • are pregnant or intend to become pregnant.
  • experience any contraction in the airways causing difficulty in breathing.
  • have any difficulty passing urine or painful urination.
  • experience eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes; these may be signs of an acute attack of narrow-angle glaucoma.

Use this medicine exactly as prescribed by your doctor or pharmacist.

Remind any doctor, dentist or pharmacist you visit that you are using SEEBRI BREEZHALER.

Things you should not do

  • Do not stop using this medicine suddenly.
  • Do not swallow SEEBRI BREEZHALER capsules.
  • Do not take more than one dose in a day.
  • Do not use this medicine to treat any other problems unless your doctor tells you to.
  • Do not give your medicine to anyone else, even if they seem to have same condition as you.
  • Do not use SEEBRI BREEZHALER in children under 18 years of age.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how SEEBRI BREEZHALER affects you.

Drinking alcohol

Tell your doctor if you drink alcohol.

Looking after your medicine

  • Follow the instructions provided in the user leaflet on how to properly clean and take care of your SEEBRI BREEZHALER
  • Store below 30°C.
  • Always store SEEBRI BREEZHALER capsules in the blister pack to protect from moisture.
  • Remove the capsules only before use.
  • Dispose of each BREEZHALER inhaler after 30 days of use.

Store it in a cool dry place away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it.

Getting rid of any unwanted medicine

Discard your SEEBRI BREEZHALER when you have no capsules left.

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effectsWhat to do
General problems:
  • Dry mouth
  • Vomiting
  • Diarrhoea
  • Difficulty sleeping
  • Fatigue
  • Unusual weakness
  • Headache
  • Numbness
  • Stomach discomfort
Respiratory Problems:
  • Sinus congestion (feeling of tension or fullness in the nose, cheeks and behind your eyes, sometimes with a throbbing ache, fever, stuffy nose and loss of the sense of smell)
  • Chesty cough
  • Sore throat
  • Hoarse voice
Muscle problems:
  • Pain in muscles, bones, joints
  • Neck pain
  • Pain in arms or legs
Skin problems:
  • Rash
  • Itching
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
Signs of an allergic reaction:
  • Difficulty in breathing or swallowing, swelling of tongue, lips and face, skin rash, itching and hives
  • Difficulty breathing with wheezing or coughing
Heart problems:
  • Fast or irregular heart beats
  • Chest pain
Other problems:
  • Excessive thirst or hunger and frequent urination (symptoms of high blood sugar levels)
  • Difficulty passing urine or painful urination
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What SEEBRI BREEZHALER contains

Active ingredient
(main ingredient)		Glycopyrronium bromide (glycopyrrolate)
Other ingredients
(inactive ingredients)		Capsule fill: Lactose monohydrate and magnesium stearate.
Capsule shell components: Hypromellose, purified water, carrageenan, potassium chloride, Sunset Yellow FCF
Printing Ink: Shellac, absolute ethanol, isopropyl alcohol, propylene glycol, butan-1-ol, ammonium hydroxide, potassium hydroxide, purified water, iron oxide black
Potential allergensLactose monohydrate

Do not take this medicine if you are allergic to any of these ingredients.

What SEEBRI BREEZHALER looks like

Glycopyrronium bromide (glycopyrrolate) 50 microgram capsules:

Clear orange coloured hard capsules with black imprints. The capsules are marked with "GPL 50" and a black company logo. The capsules come in foil packs containing 30 capsules in a cardboard carton. (AUST R 191517)

BREEZHALER:

A white plastic BREEZHALER inhalation device is also supplied in the pack.

Who distributes SEEBRI BREEZHALER

Novartis Pharmaceuticals Australia Pty Limited
ABN 18 004 244 160
54 Waterloo Road
Macquarie Park NSW 2113
Telephone 1-800-671-203
Web site: www.novartis.com.au

® = Registered Trademark

This leaflet was prepared in June 2025.

(see160821c_V2 based on PI see160821i)

Published by MIMS August 2025

BRAND INFORMATION

Brand name

Seebri Breezhaler

Active ingredient

Glycopyrronium

Schedule

S4

 

1 Name of Medicine

Glycopyrronium bromide is now known as glycopyrrolate.

2 Qualitative and Quantitative Composition

Seebri hard capsules are for oral inhalation only. Seebri is also supplied with a Breezhaler inhalation device to permit oral inhalation of the contents of the capsule shell.
Each capsule contains 63 microgram glycopyrronium bromide (glycopyrrolate) equivalent to 50 microgram glycopyrronium.
The delivered dose (the dose that leaves the mouthpiece of the Seebri Breezhaler inhaler) is equivalent to 44 microgram glycopyrronium.

Excipients.

Lactose monohydrate.
For the full list of excipients, see Section 6.1.

3 Pharmaceutical Form

Inhalation powder, hard capsule.

Transparent orange capsules containing a white powder, with the product code GPL50 printed in black above a black bar and the company logo printed under a black bar.

4 Clinical Particulars

4.1 Therapeutic Indications

Seebri Breezhaler is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).

4.2 Dose and Method of Administration

Dosage.

The recommended dosage of Seebri Breezhaler is once-daily inhalation of the content of one 50 microgram Seebri capsule using the Breezhaler inhaler.

Method of administration.

Seebri capsules must be administered only by the oral inhalation route and only using the Breezhaler inhaler. Seebri capsules must not be swallowed.
Seebri Breezhaler is recommended to be administered at the same time of the day each day. If a dose is missed, the missed dose should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day.
Seebri capsules must always be stored in the blister to protect from moisture, and only removed immediately before use.
Patients who do not experience improvement in breathing should be asked if they are swallowing the medicine rather than inhaling it.
When prescribing Seebri Breezhaler patients should be instructed on correct use of the inhaler.

Patients with renal impairment.

Seebri Breezhaler can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or endstage renal disease requiring dialysis Seebri Breezhaler should be used only if the expected benefit outweighs the potential risk (see Section 4.4).

Patients with hepatic impairment.

No specific studies have been conducted in patients with hepatic impairment. Seebri Breezhaler is predominantly cleared by renal excretion and therefore no major increase in exposure is expected in patients with hepatic impairment.

Geriatric patients.

Seebri Breezhaler can be used at the recommended dose in elderly patients 75 years of age and older.

4.3 Contraindications

Hypersensitivity to any ingredients of the preparation.
Seebri capsules contain lactose. Therefore, patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.4 Special Warnings and Precautions for Use

Not for acute use.

Seebri Breezhaler is a once-daily long-term maintenance treatment and is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy.

Hypersensitivity.

Immediate hypersensitivity reactions have been reported after administration of Seebri Breezhaler. If signs suggesting allergic reactions occur, in particular, angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips, and face), urticaria, or skin rash, Seebri Breezhaler should be discontinued immediately and alternative therapy instituted.

Paradoxical bronchospasm.

As with other inhalation therapy, administration of Seebri Breezhaler may result in paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, Seebri Breezhaler should be discontinued immediately and alternative therapy instituted.

Anticholinergic effect.

Like other anticholinergic drugs, Seebri Breezhaler should be used with caution in patients with narrow-angle glaucoma or urinary retention.
Patients should be advised about signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using Seebri Breezhaler and to contact their doctor immediately should any of these signs or symptoms develop.
Prescribers and patients should be alert for signs and symptoms of prostatic hyperplasia or bladder neck obstruction (e.g. difficulty passing urine, painful urination). Instruct patients to consult a doctor immediately should any of these signs or symptoms develop.

Patients with a history of cardiovascular disease.

Patients with unstable ischemic heart disease, left ventricular heart failure, history of myocardial infarction, arrhythmia (excluding chronic stable atrial fibrillation), a history of long QT syndrome or prolonged QT interval (Fridericia method) (> 450 ms for males or > 470 ms for females) were excluded from the clinical studies; therefore, the experience in these patient groups is limited. Seebri Breezhaler must be used with caution in these patient groups.

Use in hepatic impairment.

No specific studies have been conducted in patients with hepatic impairment. Seebri Breezhaler is predominantly cleared by renal excretion and therefore no major increase in exposure is expected in patients with hepatic impairment.

Use in renal impairment.

For patients with severe renal impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m2) including those with end-stage renal disease requiring dialysis, Seebri Breezhaler should be used only if the expected benefit outweighs the potential risk (see Section 5). These patients should be monitored closely for potential adverse drug reactions.

Use in the elderly.

Seebri Breezhaler can be used at the recommended dose in elderly patients 75 years of age and older.

Pediatric use.

Seebri Breezhaler should not be used in patients under 18 years of age, COPD is an indication of adults only.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

The co-administration of Seebri Breezhaler with inhaled anticholinergic-containing drugs has not been studied and is therefore, like for other anticholinergics, not recommended.
Concomitant administration of Seebri Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both drugs did not affect the pharmacokinetics of either drug.
In a clinical study in healthy volunteers, cimetidine, an inhibitor of organic cation transport which is thought to contribute to the renal excretion of glycopyrronium, increased total exposure (AUC) to glycopyrronium by 22% and decreased renal clearance by 23%. Based on the magnitude of these changes, no clinically relevant drug interaction is expected when Seebri Breezhaler is coadministered with cimetidine or other inhibitors of the organic cation transport.
In vitro studies showed that Seebri Breezhaler is not likely to inhibit or induce the metabolism of other drugs, nor processes involving drug transporters. Metabolism in which multiple enzymes are involved, plays a secondary role in the elimination of glycopyrronium (see Section 5.2). Inhibition or induction of metabolism of glycopyrronium is unlikely to result in a relevant change of systemic exposure to the drug.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Male and female fertility were unaffected in rats given glycopyrronium bromide (glycopyrrolate) by subcutaneous administration at doses up to 1.5 mg/kg/day (yielding plasma AUC levels approximately 900-times [males] and 500-times [females] that of humans at the maximum recommended clinical dose of 50 microgram). Slight inhibition of ovulation (decreased corpora lutea) and increased pre-implantation loss were evident at this highest dose, but not at 0.5 mg/kg/day (relative exposure based on AUC, 162).
(Category B3)
No clinical data on exposed pregnancies in COPD patients are available. Glycopyrronium bromide (glycopyrrolate) was not teratogenic in rats or rabbits following inhalational administration at doses up to 3.05 and 3.5 mg/kg/day in the respective species (yielding plasma AUC values 730-times and 250-times higher than in patients at the maximum recommended human dose). Decreased birthweight and postnatal bodyweight gain were observed in the offspring of rats given the drug by subcutaneous administration at 1.5 mg/kg/day during gestation and lactation; there was no effect at 0.5 mg/kg/day (estimated relative exposure, 162). Glycopyrronium bromide (glycopyrrolate) and its metabolites did not significantly cross the placental barrier of pregnant mice, rabbits and dogs. In human parturients undergoing Caesarean section, 86 minutes after a single intramuscular injection of 0.006 mg/kg glycopyrronium bromide (glycopyrrolate), umbilical plasma concentrations were low. As there is no adequate experience in pregnant women, Seebri Breezhaler should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the fetus.
 It is not known whether glycopyrronium bromide (glycopyrrolate) passes into human breast milk. However, glycopyrronium bromide (including its metabolites) was excreted into the milk of lactating rats up to 10-fold higher concentrations in the milk than in the blood of the dam and inhibition of postnatal bodyweight gain weight was observed in the species (see Use in pregnancy). The use of Seebri Breezhaler by breastfeeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Summary of the safety profile.

The safety and tolerability of Seebri Breezhaler has been explored at the recommended dose of 50 microgram once-daily in 1353 COPD patients. Of these, 842 patients have been treated for at least 26 weeks, and 351 patients for at least 52 weeks. There are no safety data beyond 1 year of treatment.
The safety profile is characterized by symptoms related to the anticholinergic effect including dry mouth while other gastrointestinal effects and signs of urinary retention were infrequent. Adverse drug reactions related to local tolerability included throat irritation, nasopharyngitis, rhinitis and sinusitis. At the recommended dose Seebri Breezhaler is devoid of effects on blood pressure or heart rate.

Tabulated summary of adverse drug reactions from clinical trials.

Adverse drug reactions reported during the first 6 months of two pooled pivotal phase III trials of 6 and 12 months duration are listed by MedDRA system organ class (see Table 1). Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100).
In the 12 month study the following additional adverse drug reactions were more frequent on Seebri Breezhaler than on placebo: nasopharyngitis (9.0 vs 5.6%), vomiting (1.3 vs 0.7%), musculoskeletal pain (1.1 vs 0.7%), neck pain (1.3 vs 0.7%), diabetes mellitus (0.8 vs 0%).

Adverse drug reactions from spontaneous reports and literature cases (frequency not known).

The following adverse drug reaction has been reported with Seebri Breezhaler in post-marketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.

Adverse drug reactions from spontaneous reports (frequency not known).

Immune system disorders.

Angioedema; hypersensitivity.

Respiratory, thoracic and mediastinal disorders.

Paradoxical bronchospasm, dysphonia.

Skin and subcutaneous tissue disorders.

Pruritus.

Description of selected adverse drug reactions.

The most common anticholinergic adverse reaction was dry mouth. The majority of the reports of dry mouth were suspected to be drug related and of mild degree, none was severe. Rash was uncommon and generally mild.

Special populations.

In elderly patients above 75 years of age the frequency of urinary tract infection and headache were higher on Seebri Breezhaler than on placebo, with 3.0 versus 1.5% and 2.3 versus 0%, respectively.
Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

High doses of glycopyrronium may lead to anticholinergic signs and symptoms for which symptomatic treatment may be indicated.
In COPD patients, repeated orally inhaled administration of Seebri Breezhaler at total doses of 100 and 200 microgram once-daily for 28 days were well tolerated.
Acute intoxication by inadvertent oral ingestion of Seebri Breezhaler capsules is unlikely due to the low oral bioavailability (about 5%).
Peak plasma levels and total systemic exposure following i.v. administration of 150 microgram glycopyrronium bromide (equivalent to 120 microgram glycopyrronium) in healthy volunteers were respectively about 50-fold and 6-fold higher than the peak and total systemic exposure at steady-state achieved with the recommended dose (50 microgram once-daily) of Seebri Breezhaler and were well tolerated.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: anticholinergics, ATC code: R03BB06.

Mechanism of action.

Seebri Breezhaler is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once daily maintenance bronchodilator treatment of COPD. Parasympathetic nerves are the major bronchoconstrictive neural pathway in airways, and cholinergic tone is the key reversible component of airflow obstruction in COPD. Seebri Breezhaler works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells thereby dilating the airways.
Of the five known muscarinic receptor subtypes (M1-5), only subtypes M1-3 have a defined physiological function in the human lung. Glycopyrronium bromide (glycopyrrolate) is a high affinity muscarinic receptor antagonist of these three receptor subtypes. It demonstrated 4- to 5-fold selectivity for the human M3 and M1 receptors over the human M2 receptor in competition binding studies. It has a rapid onset of action as evidenced by observed receptor association/ dissociation kinetic parameters and the onset of action after inhalation in clinical studies.
The long duration of action can be partly attributed to sustained drug concentrations in the lungs as reflected by the prolonged terminal elimination half-life of glycopyrronium after inhalation via the Seebri Breezhaler inhaler in contrast to the half-life after i.v. administration (see Section 5.2). Lung pharmacokinetic data in rats following inhalation of glycopyrronium bromide (glycopyrrolate) provides further evidence for this.

Pharmacodynamic effects.

Primary pharmacodynamic effects.

Seebri Breezhaler provided consistently significant improvement in lung function (as measured by the forced expiratory volume in one second, FEV1) over 24 hours in a number of clinical pharmacodynamic and efficacy trials.
In the pivotal studies there was a rapid onset of action within 5 minutes after inhalation of Seebri Breezhaler, with an increase in FEV1 relative to baseline ranging from 0.091 L to 0.094 L. During the first 4 hours after drug administration bronchodilation was significantly greater with Seebri Breezhaler than with the long acting muscarinic antagonist tiotropium, the treatment difference ranged from 0.030 L to 0.068 L. The bronchodilator effect of Seebri Breezhaler was sustained over 24 hours. There was no evidence for tachyphylaxis to the bronchodilator effect after repeated dosing for up to 52 weeks.

Secondary pharmacodynamic effects.

The effect on heart rate and QTc interval of glycopyrronium bromide (glycopyrrolate) 150 microgram (equivalent to 120 microgram glycopyrronium) administered intravenously was investigated in young healthy subjects. Peak exposures (Cmax) about 50-fold higher than after inhalation of Seebri Breezhaler 50 microgram at steady state were achieved and did not result in tachycardia or QT(c) prolongation. Negligible signs of bradycardia were observed (mean difference over 24 h -2 bpm when compared to placebo), which is a known effect of low exposures to anticholinergic compounds in young healthy subjects. In a thorough QT study in 73 healthy volunteers, a single inhaled dose of Seebri Breezhaler 352 microgram (8 times the therapeutic dose) did not prolong the QTc interval and slightly reduced heart rate (maximal effect 5.9 bpm; average effect over 24 hours 2.8 bpm) when compared to placebo. No changes in heart rate or QT(c) interval were observed with Seebri Breezhaler 200 microgram in COPD patients.

Clinical trials.

The Seebri Breezhaler phase III clinical development program consisted of two key efficacy and safety studies (a 6 month placebo controlled study and a 12 month placebo and active controlled study) which enrolled 1888 patients with a clinical diagnosis of COPD, who were 40 years old or older, had a smoking history of at least 10 pack years, had a postbronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value and a postbronchodilator FEV1/FVC ratio of less than 70%. Efficacy and safety of Seebri Breezhaler beyond 1 year has not been evaluated.

Lung function.

In these studies, Seebri Breezhaler, administered at 50 microgram once daily showed clinically meaningful improvements in lung function (as measured by the forced expiratory volume in one second, FEV1) over 24 hours. At the 12 week primary endpoint (24 hour trough FEV1), Seebri Breezhaler provided bronchodilation benefits of 0.108 L and 0.097 L compared to placebo (p < 0.001) for the 6 and 12 month study respectively. In the latter study, the improvement vs. placebo for the open label tiotropium 18 microgram once daily arm was 0.083 L (p < 0.001).
In both studies Seebri Breezhaler demonstrated a rapid onset of bronchodilator effect. In the 6 month study the increase in FEV1 was 0.093 L compared to placebo at 5 minutes, increasing to 0.144 L at 15 minutes after the first dose. In the 12 month study the increase in FEV1 was 0.087 L at 5 minutes and 0.143 L at 15 minutes after the first dose compared to placebo (p < 0.001). In the 12 month study, Seebri Breezhaler also produced statistically significant improvements in FEV1 compared to tiotropium in the first 4 hours after dosing on day 1 by 0.056 L (p < 0.001) and at week 26 by 0.050 L (p = 0.005), and numerically greater values for FEV1 in the first 4 hours after dosing than tiotropium at week 12 (0.030 L) and week 52 (0.015 L).
In the pivotal studies there was a rapid onset of action within 5 minutes after inhalation of Seebri Breezhaler, with an increase in FEV1 relative to baseline ranging from 0.091 L to 0.094 L.
The improvements in mean trough FEV1 observed at the primary endpoint (12 weeks) were maintained throughout treatment in both the 6- and 12-months studies. Mean trough FEV1 was increased by 0.113 L at Week 26 in the 6-month study and 0.108 L at Week 52 in the 12-month study, compared to placebo. These data indicate that the 24-hour bronchodilator effect of Seebri Breezhaler was maintained from the first dose throughout a one-year period.
In the 6-month study serial spirometry was performed on Day 1 (see Figure 1), Week 12 (see Figure 2) and Week 26. In the 12-month study serial spirometry was performed on Day 1 (see Figure 3), Week 12 (see Figure 4) and Week 52.
Serial spirometry data was used to calculate FEV1 standardized (for time) area under the curve (AUC). In the 6 month study for FEV1 AUC 0-24h Seebri Breezhaler provided a benefit of 0.133 L and 0.199 L compared to placebo at week 12 and week 26 respectively (p < 0.001). In the 12 month study at week 12, Seebri Breezhaler provided a benefit of 0.106 L for FEV1 AUC 0-24h (p < 0.001) compared to placebo; for tiotropium the treatment difference was 0.079 L compared to placebo (p = 0.014). At week 52 in the 12 month study Seebri Breezhaler provided a benefit of 0.106 L for FEV1 AUC 0-24h compared to placebo (p < 0.001); for tiotropium the treatment difference compared to placebo was 0.040 L (p = 0.279).
The magnitude of the bronchodilator effect with Seebri Breezhaler was dependent on the degree of reversibility of airflow limitation at baseline (tested by administration of a short acting muscarinic antagonist bronchodilator): patients with the lowest degree of reversibility at baseline (< 5%) generally exhibited a lower bronchodilator response than patients with a higher degree of reversibility at baseline (≥ 5%). At 12 weeks (primary endpoint), Seebri Breezhaler increased trough FEV1 by 0.072 L in patients with the lowest degree of reversibility (< 5%) and by 0.113 L in those patients with a higher degree of reversibility at baseline (≥ 5%) compared to placebo (both p < 0.05). Similar findings were observed with patients receiving tiotropium. Following 12 weeks treatment with tiotropium, patients with the lowest degree of reversibility at baseline (< 5%) were found to have an increase in trough FEV1 of 0.059 L compared to placebo, while those patients with a higher degree of reversibility at baseline (≥ 5%) were found to have an increase in trough FEV1 of 0.097 L compared to placebo.
In addition to demonstrating improvements in FEV1, Seebri Breezhaler consistently improved forced vital capacity (FVC) and inspiratory capacity (IC) in the two pivotal studies. At week 12 Seebri Breezhaler was shown to increase mean trough FVC by 0.194 L and 0.183 L compared to placebo (p < 0.001) in the 6 and 12 month studies respectively. Seebri Breezhaler improved trough IC at week 12 by 0.097 L and 0.129 L (p ≤ 0.001) compared to placebo in the 6 and 12 month studies, respectively.

Symptomatic benefit.

Seebri Breezhaler administered at 50 microgram once daily significantly reduced breathlessness as evaluated by the Transitional Dyspnea Index (TDI). In a pooled analysis of the 6 and 12 month pivotal studies the percentage of patients responding with a clinically meaningful difference of ≥ 1 point improvement in the TDI focal score at week 26 was 58.4% for Seebri Breezhaler compared with 46.4% for patients receiving placebo and 53.4% for patients receiving tiotropium. The differences in responder rates were statistically significant for the comparison of Seebri Breezhaler to placebo (< 0.001) and tiotropium to placebo (p = 0.009).
Seebri Breezhaler 50 microgram once daily has also a significant effect on health status measured using the St. George's Respiratory Questionnaire (SGRQ). A pooled analysis of the 6 and 12 month pivotal studies found the percentage of patients responding with a clinically important improvement in the SGRQ total score (≤ -4) at week 26 was 57.8% for Seebri Breezhaler compared with 47.6% for patients receiving placebo and 61.0% for patients receiving tiotropium. The differences in responder rates were statistically significant for the comparison of Seebri Breezhaler to placebo (< 0.001) and tiotropium to placebo (p = 0.004).
In a pooled analysis of the 6 and 12 month studies, Seebri Breezhaler 50 microgram once daily significantly prolonged the time to first moderate or severe COPD exacerbation and reduced the rate of moderate or severe COPD exacerbations (moderate exacerbations were those requiring treatment with systemic corticosteroids and/or antibiotics, severe exacerbations those resulting in hospitalisation). The proportion of patients with moderate or severe COPD exacerbations in the 26 week pooled analysis was 19.8% for Seebri Breezhaler vs. 27.2% for placebo and the estimated risk ratio for time to moderate or severe exacerbations was 0.64 [95% CI: 0.520, 0.799; p < 0.001], suggesting a 36% risk reduction vs. placebo, similarly the estimated risk ratio for time to first severe exacerbation leading to hospitalization was 0.39 [95% CI: 0.205, 0.728; p = 0.003]. Over the 26 week pooled analysis the exacerbation rate was statistically significantly lower for patients treated with Seebri Breezhaler compared to those treated with placebo, the rate ratio being 0.66 ([95% CI: 0.525, 0.841; p < 0.001]).
Seebri Breezhaler 50 microgram once daily significantly reduced the use of rescue medication by 0.46 puffs per day (p = 0.005) over 26 weeks and by 0.37 puffs per day (p = 0.039) over 52 weeks compared to placebo for the 6 and 12 month studies, respectively.
The effect of Seebri Breezhaler reducing dynamic hyperinflation and the associated improvements in exercise tolerance were investigated in a randomised, double blind, placebo controlled, crossover trial with a treatment duration of three weeks in 108 patients with moderate to severe COPD. Seebri Breezhaler achieved its full effect of improving inspiratory capacity under exercise (0.23 L) and has statistically significant effects on exercise endurance of 43 seconds (an increase of 10%) after the first dose. After three weeks of treatment Seebri Breezhaler improved exercise endurance time by 89 seconds (an increase of 21%) and inspiratory capacity under exercise was increased by 0.20 L. Seebri Breezhaler was found to decrease dyspnoea and leg discomfort when exercising as measured using Borg scales. Seebri Breezhaler also reduced dyspnoea at rest measured using the Transitional Dyspnoea Index.

5.2 Pharmacokinetic Properties

Absorption.

Following oral inhalation using the Seebri Breezhaler inhaler, glycopyrronium was rapidly absorbed and reached peak plasma levels at 5 minutes postdose.
The absolute bioavailability of glycopyrronium inhaled via Seebri Breezhaler inhaler was estimated to be about 40%. About 90% of systemic exposure following inhalation is due to lung absorption and 10% is due to gastrointestinal absorption. The absolute bioavailability of orally administered glycopyrronium was estimated to be about 5%.
Following repeated once daily inhalation in patients with COPD, PK steady state of glycopyrronium was reached within one week of treatment. The steady-state mean peak and trough plasma concentrations of glycopyrronium for a 50 microgram once daily dosing regimen were 166 picogram/mL and 8 picogram/mL, respectively. With once daily doses of 100 and 200 microgram, steady-state exposure to glycopyrronium (AUC over the dosing interval) was about 1.4- to 1.7-fold higher than after the first dose. Urinary excretion data at steady state compared to the first dose suggest that systemic accumulation is independent of dose in the dose range of 25 to 200 microgram.

Distribution.

After i.v. dosing, the steady-state volume of distribution (Vss) of glycopyrronium was 83 L and the volume of distribution in the terminal phase (Vz) was 376 L. The apparent volume of distribution in the terminal phase following inhalation (Vz/F) was 7310 L, which reflects the much slower elimination after inhalation. The in vitro human plasma protein binding of glycopyrronium was 38% to 41% at concentrations of 1 to 10 nanogram/mL. These concentrations were at least 6-fold higher than the steady-state mean peaks levels achieved in plasma for a 50 microgram once daily dosing regimen.

Metabolism.

In vitro metabolism studies showed consistent metabolic pathways for glycopyrronium bromide (glycopyrrolate) between animals and humans. No human specific metabolites were found. Hydroxylation resulting in a variety of mono- and bis-hydroxylated metabolites and direct hydrolysis resulting in the formation of a carboxylic acid derivative (M9) were seen.
In vitro investigations showed that multiple CYP isoenzymes contribute to the oxidative biotransformation of glycopyrronium. The hydrolysis to M9 is likely to be catalyzed by members from the cholinesterase family.
After inhalation, systemic exposure to M9 was on average in the same order of magnitude as the exposure to the parent drug. Since in vitro studies did not show lung metabolism and M9 was of minor importance in the circulation (about 4% of parent drug Cmax and AUC) after i.v. administration, it is assumed that M9 is formed from the swallowed dose fraction of orally inhaled glycopyrronium bromide (glycopyrrolate) by presystemic hydrolysis and/or via first-pass metabolism. After inhalation as well as i.v. administration, only minimal amounts of M9 were found in the urine (i.e. ≤ 0.5% of dose). Glucuronide and/or sulfate conjugates of glycopyrronium were found in urine of humans after repeated inhalation, accounting for about 3% of the dose.
In vitro inhibition studies demonstrated that glycopyrronium bromide (glycopyrrolate) has no relevant capacity to inhibit CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4/5, the efflux transporters MDR1, MRP2 or MXR, and the uptake transporters OCT1 or OCT2. In vitro enzyme induction studies did not indicate a clinically relevant induction by glycopyrronium bromide (glycopyrrolate) for any of the cytochrome P450 isoenzymes tested as well as for UGT1A1 and the transporters MDR1 and MRP2.

Excretion.

After i.v. administration of [3H]-labelled glycopyrronium bromide (glycopyrrolate) to humans, the mean urinary excretion of radioactivity in 48 h amounted to 85% of the dose. A further 5% of the dose was found in the bile. Thus, mass balance was almost complete.
Renal elimination of parent drug accounts for about 60 to 70% of total clearance of systemically available glycopyrronium whereas nonrenal clearance processes account for about 30 to 40%. Biliary clearance contributes to the nonrenal clearance, but the majority of nonrenal clearance is thought to be due to metabolism.
Following inhalation of single and repeated once daily doses between 50 and 200 microgram glycopyrronium by healthy volunteers and patients with COPD mean renal clearance of glycopyrronium was in the range of 17.4 and 24.4 L/h. Active tubular secretion contributes to the renal elimination of glycopyrronium. Up to 20% of the dose was found in urine as parent drug.
Glycopyrronium plasma concentrations declined in a multiphasic manner. The mean terminal elimination half-life was much longer after inhalation (33 to 57 hours) than after intravenous (6.2 hours) and oral (2.8 hours) administration. The elimination pattern suggests a sustained lung absorption and/or transfer of glycopyrronium into the systemic circulation at and beyond 24 h after inhalation.

Linearity/ nonlinearity.

In COPD patients' systemic exposure as well as total urinary excretion of glycopyrronium at pharmacokinetic steady state increased about dose proportionally over the dose range of 50 microgram to 200 microgram.

Pharmacokinetics in special patient groups.

Patients with hepatic impairment.

Clinical studies in patients with hepatic impairment have not been conducted. Glycopyrronium is cleared predominantly from the systemic circulation by renal excretion (see Section 5.2). Impairment of the hepatic metabolism of glycopyrronium is not thought to result in a clinically relevant increase of systemic exposure.

Patients with renal impairment.

Renal impairment has an impact on the systemic exposure to glycopyrronium bromide (glycopyrrolate). A moderate mean increase in total systemic exposure (AUClast) of up to 1.4-fold was seen in subjects with mild and moderate renal impairment and up to 2.2-fold in subjects with severe renal impairment and end stage renal disease. Using a population PK analysis, it was concluded that in COPD patients with mild and moderate renal impairment (estimated glomerular filtration rate eGFR ≥ 30 mL/min/1.73 m2) Seebri Breezhaler can be used at the recommended dose.

Ethnicity.

There were no major differences in total systemic exposure (AUC) between Japanese and Caucasian subjects following inhalation of glycopyrronium bromide (glycopyrrolate). Insufficient PK data is available for other ethnicities or races.

Bodyweight and age.

A population PK analysis of data in COPD patients identified bodyweight and age as factors contributing to interpatient variability in systemic exposure. Seebri Breezhaler 50 microgram once daily can be safely used in all age and bodyweight groups.

Effects of gender, smoking status and baseline FEV1.

Gender, smoking status and baseline FEV1 had no apparent effect on systemic exposure.

5.3 Preclinical Safety Data

Genotoxicity.

Glycopyrronium bromide (glycopyrrolate) was not genotoxic in assays for bacterial mutagenicity, chromosomal aberrations in vitro (human lymphocytes) or in vivo clastogenicity (rat bone marrow micronucleus test).

Carcinogenicity.

Carcinogenicity studies of six months duration in transgenic mice (rasH2) using oral administration and 2 years duration in rats using inhalation administration revealed no evidence of carcinogenicity with glycopyrronium bromide (glycopyrrolate). The highest dose levels employed (75 and 100 mg/kg/day in male and female mice and 0.45 mg/kg/day in rats) were associated with systemic exposures (AUC) of approximately 53-fold higher in mice and 79-fold higher in rats than in humans at the maximum recommended dose of 50 microgram once daily. The lung deposited dose in rats (per unit alveolar surface area) was up to almost 200-fold higher than the level anticipated in patients.

6 Pharmaceutical Particulars

6.1 List of Excipients

Capsule fill.

Lactose monohydrate and magnesium stearate.

Capsule shell components.

Hypromellose, purified water, carrageenan, potassium chloride, Sunset Yellow FCF.

Printing ink.

Shellac, absolute ethanol, isopropyl alcohol, propylene glycol, butan-1-ol, ammonium hydroxide, potassium hydroxide, purified water, iron oxide black.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 30°C. Protect from moisture.

6.5 Nature and Contents of Container

Carton containing 10 Seebri capsules and one Breezhaler inhaler.
Carton containing 30 Seebri capsules and one Breezhaler inhaler.
Multipack comprising 3 packs (each containing 30 Seebri capsules and one Breezhaler inhaler).
Not all pack sizes may be marketed.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.


Chemical name (IUPAC): 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium bromide. Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide-3-hydroxy-1,1-dimethylpyrrolidinium bromide α-cyclopentylmandelate.
INN/AAN: Glycopyrronium bromide (glycopyrrolate).
CAS name: Pyrrolidinium, 3-[(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethyl-, bromide (1:1).

CAS no.

596-51-0.
Molecular formula: C19H28NO3.Br.
Molecular weight: Salt form: 398.33.
Stereochemistry: 2 asymmetric carbon atoms and is an optically inactive racemic mixture of 2 stereoisomers (S,R) and (R,S).
Aqueous solubility: At 25°C freely soluble in aqueous media across the pH range from 1 to 10 (water solubility > 100 mg/mL).
Partition coefficient: Distribution coefficient D in Octanol/Water at 37.0 +/- 0.5°C: 0.060 (log D = -1.2).
pKa: Glycopyrronium bromide (glycopyrrolate) is a quaternary ammonium salt and permanently ionized between pH 1 and 14.

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription Only medicine.

Summary Table of Changes